TICKERNERD
Menu
SMTISMTIHealthcare · Medical Instruments & Supplies

SMTI Stock Forecast: Sanara MedTech, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$35
+0.26% on the day

The 3 Wall Street analysts covering Sanara MedTech, Inc. hold a median 12-month price target of $35 — -0.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 19 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$322.2M
Ticker Nerd rank
92 / 100
Median analyst target
$35
Analysts covering
3
Revenue$28.1M+8.9% y/y
Operating income$1.8M
Net income−$453K
Free cash flow$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.4%
1M
+2.6%
YTD
+50.2%
1Y
+1.2%
From 52W high
−0.1%
From 52W low
+114.6%
$16
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SMTI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sanara MedTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Accruals
94
Value
74
Revisions
72
Momentum
69
Size
60
Volatility
60
Growth
60
Issuance
25

Quality (97): The business earns solid, repeatable profits on what it owns.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SMTI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SMTI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26SMTIHigh $35Median $35Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
0 Buy3 Hold0 Sell
Low $35Median $35High $35

The green dot is the last close — the median target sits −0.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 July 2026HC Wainwright & Co.DowngradeNeutral$36 → $35
17 June 2026Freedom BrokerInitiatesBuy$35
17 June 2026Freedom BrokerInitiatesBuy—
15 Apr 2026Lake StreetInitiatesBuy—
26 Jan 2026HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
18 Aug 2025HC Wainwright & Co.MaintainsBuy—
18 Aug 2025HC Wainwright& Co.MaintainsBuy—
15 May 2025HC Wainwright & Co.MaintainsBuy—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
26 Mar 2025HC Wainwright & Co.MaintainsBuy—
23 Jan 2025Cantor FitzgeraldReiteratesOverweight—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025Cantor FitzgeraldReiteratesOverweight—
23 Dec 2024HC Wainwright & Co.InitiatesBuy—
15 May 2024Cantor FitzgeraldReiteratesOverweight—
27 Mar 2024Cantor FitzgeraldMaintainsOverweight—
6 Feb 2024Cantor FitzgeraldReiteratesOverweight—
15 Nov 2023Cantor FitzgeraldMaintainsOverweight—
26 Sept 2023Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMTI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SMTI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Sanara MedTech, Inc. returned +1.2% against +16.3% for the S&P 500, dividends included.

SMTI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26SMTIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SMTI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+11.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Sanara MedTech, Inc. (SMTI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
58.2×

Cheaper than 12% of US stocks

Price / sales
2.9×

Cheaper than 42% of US stocks

Price / book
45.7×

Cheaper than 2% of US stocks

EV / EBITDA
27.9×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
9.0%

Higher than 49% of US stocks

Earnings growth (YoY)
8.9%

Higher than 47% of US stocks

Gross margin
93.0%

Higher than 97% of US stocks

Operating margin
6.3%

Higher than 58% of US stocks

Net margin
−29.2%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−1.3%

Higher than 42% of US stocks

Return on assets
7.6%

Higher than 87% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sanara MedTech, Inc. (SMTI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sanara MedTech, Inc. has a market value of $322.2M and an enterprise value of $355.3M.

  • Revenue in the twelve months to 30 June 2026: $109.8M. The latest quarter grew 9.0% year on year.

  • Net income over the same four quarters: −$32.0M, a −29.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.71.

  • Free cash flow in the twelve months to 30 June 2026: $4.5M.

  • Shares outstanding: 9.2M.

  • Trailing P/E: 58.2×; forward P/E: 64.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sanara MedTech, Inc. employs 108 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

SMTI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
SMTISanara MedTech, Inc.$322.2M
92
EMBCEmbecta Corp.$313.3M
84
OSUROraSure Technologies, Inc.$246.1M
89
UTMDUtah Medical Products, Inc.$235.5M
79
PDEXPro-Dex, Inc.$231.6M
94
ANGOAngioDynamics, Inc.$636.1M
91
ZJYLJin Medical International Ltd.$156.1M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sanara MedTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SMTI news & analysis

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

Business Wire · 10 Sept 2026negative

Law firm Kahn Swick & Foti, LLC, along with former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed sale of Sanara MedTech Inc. to MiMedx Group, Inc. Under the proposed transaction, Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and the firm is examining whether the consideration and process are adequate.

Why it matters — An investor-law firm probing the deal's fairness signals potential scrutiny of the proposed acquisition terms that Sanara shareholders would receive.

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 29 Aug 2026negative

Investor rights law firm Halper Sadeh LLC announced it is investigating the sale of Sanara MedTech Inc. to MiMedx Group, Inc., under which Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share. The firm is examining whether the transaction provides a fair price to Sanara shareholders and is inviting shareholders to learn about their rights.

Why it matters — SMTI watchers would care because an investor-rights probe raises scrutiny over the fairness of the merger consideration and could signal shareholder concerns about the deal's value.

Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates

Zacks Investment Research · 12 Aug 2026positive

Sanara MedTech Inc. reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This compares favorably to a loss of $0.23 per share in the same quarter last year.

Why it matters — The company exceeded analyst expectations and showed a significant year-over-year improvement, swinging from a loss to profitability.

Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)

GlobeNewsWire · 11 Aug 2026neutral

Sanara MedTech Inc. reported its unaudited financial results for the second quarter ended June 30, 2026. The announcement covers the company's performance for the period in its surgical market focus.

Why it matters — SMTI watchers would care because the quarterly financial results provide a regular update on the company's operational and financial performance.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)

GlobeNewsWire · 4 Aug 2026negative

Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving several companies, including Sanara MedTech Inc. (Nasdaq – SMTI). The firm invites shareholders to discuss the investigation at no cost or financial obligation.

Why it matters — The notice signals that Sanara MedTech is the subject of a law-firm investigation, which could be of concern to SMTI watchers and shareholders.

FAQ

Frequently asked questions about SMTI stock

What is the SMTI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Sanara MedTech, Inc. have a median 12-month price target of $35, with estimates ranging from $35 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SMTI stock a buy right now?

Of the 3 analysts covering Sanara MedTech, Inc., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sanara MedTech, Inc. 92 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SMTI?

As at 19 Sept 2026, Sanara MedTech, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will SMTI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies -0.2% from the last close, and Ticker Nerd's factor model ranks Sanara MedTech, Inc. 92 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SMTI stock forecast for 2030?

No analyst covering Sanara MedTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $35 over the next 12 months.

How has SMTI stock performed over the past year?

Sanara MedTech, Inc. returned +1.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sanara MedTech, Inc. do?

Sanara MedTech Inc. is a medical technology company that develops, markets, and distributes surgical, wound care, and skin care solutions for physicians, hospitals, clinics, and post-acute care providers.

What is the latest news on SMTI?

The most recent item we track (Business Wire, 10 Sept 2026): "Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI". Law firm Kahn Swick & Foti, LLC, along with former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed sale of Sanara MedTech Inc. to MiMedx Group, Inc. Under the proposed transaction, Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and the firm is examining whether the consideration and process are adequate.

Company

About Sanara MedTech, Inc.

Sanara MedTech Inc. is a medical technology company that develops, markets, and distributes surgical, wound care, and skin care solutions for physicians, hospitals, clinics, and post-acute care providers. Its portfolio includes products used in surgical tissue repair, advanced wound management, infection control, and skin cleansing, supporting clinical workflows across a range of care settings. The company focuses on evidence-based technologies designed to help improve healing outcomes and address complex tissue health needs. Sanara MedTech Inc. serves healthcare professionals in the United States through a product mix that spans surgical adjuncts, biologic materials, wound care devices, and antimicrobial cleansers. Based in Fort Worth, Texas, Sanara MedTech Inc. plays a role in the medical products market by supplying specialized solutions for surgical and chronic wound treatment.

CEO Mr. Seth D. Yon · 108 employees · United States · https://sanaramedtech.com